UNSPSC 51141599: Cannabidiol CBD

FDA approved Schedule V hemp or cannabis derivative

UNSPSC 51141599 Cannabidiol CBD is a Commodity code, but the recent state and local opportunities posted under it do not involve cannabidiol or CBD products. Instead, they reflect procurement of opioid antagonists (naloxone), drug deactivation systems, generic pharmaceuticals, and pharmacy benefit program infrastructure — product categories and services outside the nominal scope of this code. The mismatch between the code designation and the actual work being solicited suggests either miscoding in the state and local procurement systems or a data classification issue that obscures the true activity under this Commodity code.

The three recent opportunities span different issuing bodies and procurement models: Seminole County, Florida posted an IFB for 1,900 units of naloxone and 800 drug deactivation systems annually (response deadline Jul 26, 2023); the Texas Health and Human Services Commission issued an RFI on Apr 3, 2026 to gather market intelligence on direct-to-manufacturer pharmacy programs; and the Minnesota Multistate Cooperative Purchasing Alliance released an RFP on Jan 20, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local governments, with proposals due Mar 26, 2026. These opportunities indicate activity from county health departments, state health agencies, and cooperative purchasing vehicles, but none directly address cannabidiol procurement. Until state and local procurement offices post solicitations for CBD products under this code, or the code is correctly applied to mislabeled opportunities, this Commodity code shows no relevant recent activity for vendors targeting CBD markets in state and local government procurement.